Astec Lifesciences Limited (ASTEC) AI Stock Analysis

• Market Cap: ₹14.00B
• Dividend Yield: N/A
• Average Volume (3M): 412.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 1.54%
• EPS Growth: -8.04%
• Country: IN
• Employees: 606
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): -7.04
• Shares Outstanding: 22,281,660
• 10 Day Avg. Volume: 47,730
• 30 Day Avg. Volume: 412,490
• PEG Ratio: -0.06
• Price to Book (P/B): 6.06
• Price to Sales (P/S): 3.73
• P/FCF Ratio: -47.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -21.45
• Revenue Forecast (FY): ₹4.60B

• Rating: 52 Neutral
• Price Target: ₹635.00 ▼(-9.74% Downside)
• Action: Reiterated Date: 12/02/25
• Date: Action: Reiterated 12/02/25

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenue, negative margins, and liquidity issues. While technical analysis shows positive momentum, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a moderate overall score.

Positive Factors

Product Mix & Vertical Integration

Astec sells technical actives, intermediates and finished formulations, giving it multiple revenue streams across the crop‑protection value chain. This vertical exposure can protect margins when one segment softens, enable cross‑selling, and capture value from both manufacturing and formulation over a multi‑month to multi‑year horizon.

Positive Shareholders' Equity Buffer

Despite stresses, the balance sheet still shows positive shareholders' equity, providing a capital buffer against losses. That persistent equity base supports continued operations, access to credit and potential restructuring flexibility, reducing immediate insolvency risk over the coming months.

Exposure to Structural Agchem Demand

Astec operates in crop protection, an industry driven by enduring agricultural productivity needs and crop yield pressures. Structural demand for agrochemicals tends to be stable over years, supporting a steady addressable market for actives, intermediates and formulations irrespective of short‑term cycles.

Negative Factors

Declining Revenue & Negative Margins

Revenue has fallen and gross and net margins turned negative, signaling weakening core profitability. Sustained negative margins erode reinvestment capacity, deter long‑term customers and complicate efforts to return to profitability without structural changes to costs, pricing or product mix.

High Leverage & Falling Equity Ratios

An increasing debt‑to‑equity ratio and lower equity backing raise refinancing and interest‑coverage risks. High leverage constrains strategic flexibility, limits ability to fund capex or absorb input‑cost shocks, and makes the company more vulnerable to tighter credit conditions over the next several quarters.

Negative Operating and Free Cash Flow

Operating cash flow and free cash flow are negative, indicating difficulty converting reported results into cash. Persistent cash shortfalls force reliance on external financing, increase liquidity risk, and can limit working capital and investment, undermining sustainable operations and growth over months ahead.

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and intermediates, such as triazole fungicides, heterocyclic herbicides, sulfonyl urea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, and silane derivatives; fluorinated aromatic amines, pyridine derivatives, aromatic carboxylic acids, benzyl alcohols, ketones and benzophenones, and heterocyclic mercaptans; fluorinated aromatic, aliphatic, and heterocyclic intermediates; heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, heterocyclic sulfonyl chlorides, heterocyclic sulphonamides, heterocyclic carbamates, thiourium salts, alkyl and aryl chloroformates, substituted pyrimidine diones, and pyrazolones; and substituted 1,2- and 1,3- pyrimidines. The company's products also comprise pyrazolyl aromatic ketones, morpholine derivatives, aromatic azo compounds, substituted triazines, imidate ethers, mesylated intermediates, substituted epoxides, ketals and bromo ketals, aromatic and aliphatic ethers, cyclopropyl ethers, cyclopropyl aldehydes and ketones, conjugated ketones, acetophenone derivatives, pinacolone derivatives, aliphatic and aromatic carboxylic acids, aliphatic and aromatic acid chlorides, halogenated and non-halogenated anhydrides, aliphatic alkenes, and halo alkanes; and aliphatic and aromatic brominated derivatives, cyanides, esters, carboxamides, amines, and alcohols and diols. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.

How the Company Makes Money

Astec Lifesciences generates revenue primarily through the sale of its agrochemical products and pharmaceutical intermediates. The company's revenue model is built on manufacturing and distributing a diverse range of crop protection chemicals, which are sold to agricultural businesses and distributors. Key revenue streams include the sale of branded and generic agrochemicals, contract manufacturing services for third parties, and the export of products to international markets. Significant partnerships with global agricultural firms enhance its market reach and contribute to earnings through collaborative projects and joint ventures. Additionally, the company's focus on research and development allows it to introduce new products, thereby expanding its market presence and driving revenue growth.

Astec Lifesciences Limited Financial Statement Overview

Summary

Astec Lifesciences Limited faces significant financial challenges. The income statement highlights declining revenue and profitability, with negative margins impacting overall performance. The balance sheet shows high leverage and decreasing equity ratios, increasing financial risk. Cash flow difficulties, marked by negative free cash flow, further exacerbate the situation, suggesting liquidity constraints and a need for strategic financial management.

Income Statement

The income statement shows a decline in revenue from 2023 to 2025, with a significant drop in gross profit and net income, resulting in negative margins. The company has experienced negative net profit margins in the most recent years, indicating profitability issues. The revenue growth has been negative, reflecting a challenging market environment or operational difficulties.

Balance Sheet

The balance sheet indicates high leverage with an increasing debt-to-equity ratio over the years, reflecting financial risk. The equity ratio has also decreased, signaling reduced asset backing by equity. Although the company maintains a positive stockholder's equity, the increasing liabilities pose a risk to financial stability.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow in recent years, highlighting liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating a struggle to convert income into cash. Consistently negative free cash flow growth raises concerns about the company’s ability to sustain operations without external financing.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	4.03B	3.81B	4.58B	6.28B	6.77B	5.55B
Gross Profit	973.81M	-685.16M	1.33B	2.27B	2.86B	2.10B
EBITDA	-271.65M	-662.07M	-2.69M	893.14M	1.65B	1.19B
Net Income	-1.28B	-1.35B	-469.30M	255.65M	898.59M	650.49M
Balance Sheet
Total Assets	0.00	8.81B	9.75B	9.79B	8.97B	6.78B
Cash, Cash Equivalents and Short-Term Investments	5.75M	8.55M	16.47M	27.54M	33.44M	15.42M
Total Debt	0.00	5.55B	4.94B	3.41B	2.79B	1.87B
Total Liabilities	-2.35B	6.46B	6.05B	5.60B	5.00B	3.68B
Stockholders Equity	2.35B	2.35B	3.69B	4.19B	3.96B	3.09B
Cash Flow
Free Cash Flow	0.00	-302.20M	-1.25B	-426.03M	-803.74M	-1.11B
Operating Cash Flow	0.00	-83.99M	102.21M	746.56M	236.04M	-81.62M
Investing Cash Flow	0.00	-152.30M	-1.35B	-1.13B	-1.04B	-731.10M
Financing Cash Flow	0.00	237.33M	1.25B	377.70M	804.77M	813.36M

Astec Lifesciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 703.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 703.5 is above the 20-day moving average (MA) of 631.74, above the 50-day MA of 642.06, and below the 200-day MA of 756.29, indicating a bearish trend. The MACD of -2.26 indicates Negative momentum. The RSI at 48.68 is Neutral, neither overbought nor oversold. The STOCH value of 74.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PUNJABCHEM	64 Neutral	₹13.18B	26.88	―	0.24%	10.70%	32.65%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹21.74B	29.38	―	0.97%	5.74%	16.06%
IGPL	59 Neutral	₹10.26B	-28.19	―	2.59%	-10.71%	-40.89%
ASTEC	52 Neutral	₹14.00B	-25.02	―	―	1.54%	-8.04%
UNIENTER	49 Neutral	₹7.16B	-247.22	―	0.34%	―	―
HERANBA	44 Neutral	₹7.82B	-10.64	―	0.39%	―	―

Astec Lifesciences Limited Corporate Events

Astec LifeSciences Files SEBI Demat Compliance Certificate for December Quarter

Astec LifeSciences Limited has informed the Indian stock exchanges that it has received a compliance certificate from its registrar and share transfer agent, Bigshare Services Pvt. Ltd., for the quarter ended 31 December 2025, confirming adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The registrar has certified that no securities were received for dematerialisation during the quarter, and therefore no share certificates were mutilated, cancelled or had their ownership substituted in favour of depositories, underscoring a period of no demat-related activity and reinforcing the company’s ongoing regulatory compliance in its securities handling processes.